The Isotope That Changed Oncology's Commercial Landscape
Lutetium-177 is a radioactive isotope of the element lutetium that emits beta radiation with a physical half-life of approximately 6.7 days and a tissue penetration range of a few millimetres. These physical properties make it well-suited for targeted cancer therapy: when attached to a molecule that binds selectively to cancer cells, Lu-177 delivers a localised radiation dose to the tumour while sparing surrounding normal tissue to a greater extent than external beam radiation can achieve. The concept of radioligand therapy, attaching a cancer-targeting ligand to a radioactive payload, has existed for decades and has been used clinically in the form of iodine-131 for thyroid cancer for over eighty years. What changed with Lu-177 was the combination of its favourable physical properties with the development of targeting ligands that could direct it to cancer cell types beyond thyroid cancer, particularly to neuroendocrine tumours and to prostate cancer through prostate-specific membrane antigen targeting.
The commercial pivotal moment for Lu-177 came with the NETTER-1 trial results that led to the FDA approval of Novartis's Lutathera in 2018 for somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumours, and more consequentially for the commercial scale of the Lu-177 market, with the VISION trial results that led to the 2022 FDA approval of Pluvicto for PSMA-positive metastatic castration-resistant prostate cancer. Prostate cancer is one of the most prevalent cancers in men, and the approval of Pluvicto for a late-line prostate cancer indication created demand for Lu-177 radioligand therapy at a scale that the existing radioisotope supply infrastructure was not built to serve. The supply-demand imbalance that followed Pluvicto's approval created waiting lists for patients whose prescriptions could not be filled because the Lu-177 required to manufacture the drug could not be produced at the rate that the approved indication's patient population demanded.
The Supply Chain That Cannot Scale Fast Enough
Lu-177 is produced in nuclear reactors by neutron bombardment of either lutetium-176 target material, which yields reactor-produced non-carrier-added Lu-177 with the specific activity required for radioligand therapy, or by neutron bombardment of ytterbium-176, which produces high specific activity Lu-177 through the decay of ytterbium-177. The reactor-produced Lu-177 that the commercial radioligand therapy market depends on is available from a limited number of high-flux research reactors worldwide, including reactors operated by the Institute for Radioelements in Belgium, the Institute for Energy Technology in Norway, the High Flux Reactor at NRG in the Netherlands, and several reactors in Russia and China. The concentration of Lu-177 production capacity in a small number of specialised reactor facilities whose expansion requires significant capital investment, long lead times for equipment procurement and installation, and regulatory approval for nuclear material production creates a structural supply constraint that cannot be resolved quickly even when the commercial incentive to expand production is substantial.
The radiopharmaceutical manufacturing infrastructure that converts reactor-produced Lu-177 into finished radioligand therapy doses adds a further capacity constraint to the supply chain. The short half-life of Lu-177 requires that the radioligand labelling, quality control, and distribution of finished product occur within a compressed timeframe that imposes geographic constraints on the distribution network. A radioligand therapy dose manufactured at a central facility has a limited useful life that determines the maximum distribution radius within which it can be delivered to a clinical facility in a state suitable for patient administration. The regionalisation of radioligand therapy manufacturing, in which multiple manufacturing sites are established within the distribution radius of major patient populations rather than relying on centralised production and long-distance distribution, is the supply chain solution that the commercial radioligand therapy market is implementing to close the gap between production capacity and patient demand.
The Pipeline Beyond Prostate Cancer
The commercial significance of Lu-177 extends beyond the currently approved Lutathera and Pluvicto indications to a pipeline of radioligand therapy programmes that target additional cancer types with Lu-177 conjugated to different targeting ligands. Bristol-Myers Squibb's acquisition of RayzeBio in 2024 for 4.1 billion dollars was a direct bet on the Lu-177 radioligand therapy pipeline in additional indications including gastric and liver cancers targeted through actinium-based radionuclides as well as Lu-177. Eli Lilly's acquisition of Point Biopharma in 2023 for 1.4 billion dollars provided access to Point's Lu-177 radioligand therapy manufacturing infrastructure and its pipeline of radioligand therapy candidates. AstraZeneca's acquisition of Fusion Pharmaceuticals in 2024 for 2 billion dollars added a radiopharmaceutical pipeline that includes Lu-177 and actinium-225 conjugates targeting multiple cancer indications. The pattern of large pharmaceutical company acquisitions of radiopharmaceutical developers at substantial premiums reflects the commercial assessment that the Lu-177 radioligand therapy market whose near-term scale is defined by prostate cancer has a medium-term expansion potential across multiple additional cancer indications that justifies aggressive commercial positioning now.
Top 10 Companies in Lutetium-177 Radiopharmaceuticals Globally
- Novartis: Owns both Lutathera and Pluvicto, the only FDA-approved Lu-177 radioligand therapies; its investment in radioligand therapy manufacturing capacity expansion and its PSMA-617 development programme for earlier prostate cancer lines make it the most commercially committed large pharma company in the Lu-177 market with the largest approved revenue base.
- Bristol-Myers Squibb (RayzeBio): Acquired RayzeBio for 4.1 billion dollars in 2024 for its actinium-225 and Lu-177 radiopharmaceutical pipeline targeting gastric, hepatocellular, and additional solid tumours; its pipeline includes RYZ101 targeting SSTR2 in gastroenteropancreatic NETs and demonstrates BMS's conviction that radioligand therapy will expand beyond prostate cancer.
- Eli Lilly (Point Biopharma): Acquired Point Biopharma for 1.4 billion dollars providing access to dedicated Lu-177 manufacturing capacity and a pipeline including PNT2002 for prostate cancer; its manufacturing infrastructure acquisition reflects the strategic priority of securing radioligand therapy production capacity whose shortage is the commercial constraint limiting the market's growth.
- AstraZeneca (Fusion Pharmaceuticals): Acquired Fusion Pharmaceuticals for 2 billion dollars in 2024 adding a radiopharmaceutical pipeline spanning Lu-177 and actinium-225 conjugates targeting multiple cancers; its FPI-2265 for mCRPC and its FPI-1434 for solid tumours expressing IGF-1R represent the pipeline diversification beyond PSMA targeting that AZ is betting on.
- Lantheus Holdings: Radiopharmaceutical company whose PYLARIFY PSMA PET diagnostic agent for prostate cancer imaging is the commercial companion to Pluvicto therapy; its diagnostic-therapeutic pairing strategy and its growing radiopharmaceutical manufacturing capabilities position it as the infrastructure company through which radioligand therapy's commercial ecosystem develops beyond the large pharma programmes.
- IRE (Institute for Radioelements): Belgian nuclear research centre producing non-carrier-added Lu-177 for radioligand therapy manufacturing; its position as one of the most significant Lu-177 production facilities globally makes it the supply chain anchor whose production capacity expansion directly determines the pace at which patient access to approved radioligand therapies can grow.
- NRG (High Flux Reactor): Dutch nuclear research organisation operating the High Flux Reactor at Petten, a primary Lu-177 production source supplying European radioligand therapy manufacturers; its reactor lifetime extension and capacity optimisation are the production infrastructure investments that the European radioligand therapy supply chain depends on.
- Curium Pharma: Radiopharmaceutical manufacturing company with European and US facilities for radioligand therapy production and distribution; its manufacturing capacity for Lu-177 labelling and its distribution network for short-shelf-life radiopharmaceuticals are the commercial infrastructure whose scale determines how many patients in its served geographies can access radioligand therapy.
- Eckert and Ziegler: German radiopharmaceutical company producing PSMA-617 for Novartis's Pluvicto and developing its own radioligand therapy pipeline; its position as the manufacturer of the PSMA-617 targeting component that Novartis uses makes it the supply chain partner whose capacity is directly coupled to Pluvicto's commercial scale.
- RadioMedix: US radiopharmaceutical company developing AC-225 and Lu-177 radioligand therapies targeting multiple cancer indications; its focus on actinium-225 as a complementary alpha-emitting radionuclide to Lu-177's beta emission reflects the radiopharmaceutical field's expansion toward alpha therapy whose higher linear energy transfer may prove more effective in radioresistant tumour types.